Wondering if Organon at around $7 a share is a bargain in disguise or a value trap waiting to happen? This article is going to unpack that in plain English so you can decide for yourself.

Over the last week the stock has crept up about 1.4%, but that small uptick is set against a much harsher backdrop, with the share price down roughly 52.6% year to date and 50.6% over the past year.

That steep slide has coincided with ongoing concerns about patent cliffs in women’s health, investor skepticism about the legacy portfolio it was spun out with, and a broader rotation away from slower growth pharma names. At the same time, management has been leaning into its biosimilars and fertility franchises, trying to convince the market that…